{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:54:05Z","timestamp":1790967245676,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The accidental contamination by the use of transdermal applications of clostebol acetate has been proven by the monitoring of its main urinary metabolite 4\u2010chloro\u20103\u03b1\u2010hydroxy\u2010androst\u20104\u2010en\u201017\u2010one (M1). This work is aimed at describing clostebol metabolism in humans and at searching for specific metabolic markers or concentration thresholds allowing for distinguishing between an oral and a transdermal administration, helping to set up adequate criteria to be adopted by the antidoping community when incidental contamination is suspected. Urine samples were collected after the administration of a single dose of clostebol acetate orally (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093, males), a single transdermal dose (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091, male), and multiple transdermal administrations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093, males, and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093, females). After enzymatic hydrolysis, liquid\u2013liquid extraction, and the formation of trimethylsilyl derivatives, the samples were analyzed by gas chromatography coupled to tandem mass spectrometry and time\u2010of\u2010flight mass spectrometry. The metabolism of clostebol after oral and transdermal applications was described. Ten metabolites were detected after oral administration (M1\u2013M10), but only five (M1\u2013M4 and M9) could be detected after transdermal applications under the assay conditions applied. The use of concentrations of any metabolite might be difficult because of the interindividual variability in absorption, metabolism, and\/or excretion. Instead, the ratios between M4 and M1 showed plausible results to discriminate between both administrations under the conditions described here. The intentionality of the use of one or other route of administration cannot be assessed.\n                  <\/jats:p>","DOI":"10.1002\/dta.3953","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T10:45:30Z","timestamp":1758019530000},"page":"2399-2410","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clostebol Metabolism by Different Routes of Administration: Selection of Diagnostic Urinary Markers"],"prefix":"10.1002","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-6750","authenticated-orcid":false,"given":"Xavier","family":"de la Torre","sequence":"first","affiliation":[{"name":"Laboratorio Antidoping FMSI Federazione Medico Sportiva Italiana  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Colamonici","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI Federazione Medico Sportiva Italiana  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-4916","authenticated-orcid":false,"given":"Dayamin","family":"Mart\u00ednez_Brito","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI Federazione Medico Sportiva Italiana  Rome Italy"},{"name":"Laboratorio Antidoping of Havana Ministry of Public Health  La Habana Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-0370","authenticated-orcid":false,"given":"Rodny\u00a0Montes","family":"de Oca\u00a0Porto","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping of Havana Ministry of Public Health  La Habana Cuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-8126","authenticated-orcid":false,"given":"Francesco","family":"Botr\u00e8","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI Federazione Medico Sportiva Italiana  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2951"},{"key":"e_1_2_8_3_1","volume-title":"The Pharmacological Basis of Therapeutics","author":"Gilman A.","year":"2006"},{"key":"e_1_2_8_4_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cInternational Standard Prohibited List 2025 \u201d Montreal Quebec Canada. (2025)"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2670(93)80274-O"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.7.1001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/44.5.973"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3517"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.03.028"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2670(93)80275-P"},{"key":"e_1_2_8_11_1","first-page":"454","article-title":"Incidental Clostebol Contamination in Athletes After Sexual Intercourse","volume":"50","author":"Talhas H. M. G. P.","year":"2004","journal-title":"Clinical Chemistry"},{"key":"e_1_2_8_12_1","volume-title":"Martindale. The Complete Drug Reference","author":"Sweetman S. C.","year":"2009"},{"key":"e_1_2_8_13_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cAnti\u2010Doping Testing Figures \u201d (2024)."},{"key":"e_1_2_8_14_1","unstructured":"World Anti\u2010Doping Agency \u201cTechnical Document TD2022MRPL. Minimum Required Performance Levels and Applicable Minimum Reporting Levels for Non\u2010Threshold Substances Analyzed by Chromatographic\u2013Mass Spectrometric Analytical Methods \u201d (2022)."},{"key":"e_1_2_8_15_1","first-page":"14","article-title":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. General Principles","volume":"81","author":"World Medical Association","year":"2014","journal-title":"Journal of the American College of Dentists"},{"key":"e_1_2_8_16_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cWADA Technical Document\u2014TD2022DL Decision Limits for the Confirmatory Quantification of Exogenous Threshold Substances by Chromatography\u2010Based \u201d (2022)."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23270"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.03.005"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(92)90390-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010291527744"},{"key":"e_1_2_8_21_1","volume-title":"Skin Barrier","author":"Elias P. M.","year":"2006"},{"key":"e_1_2_8_22_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cTechnical Document TD2021IDCR\u2014Minimum Criteria for Chromatographic\u2010Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes \u201d (2021)."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470727140"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/15.4.161"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(93)80026-W"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1759"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.022848"},{"key":"e_1_2_8_28_1","unstructured":"WADA\u2010Science\/EAAS\u2010Working\u2010Group \u201cMeasurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile (TD2021EAAS) \u201d2021."},{"key":"e_1_2_8_29_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cWADA Technical Document TD2022IRMS Detection of Synthetic Forms of Prohibited Substances by GC\/C\/IRMS \u201d (2022)."},{"key":"e_1_2_8_30_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cWADA Technical Document\u2014TD2021GH Human Growth Hormone (hGH) Isoform Differential Immunoassays \u201d (2021):1\u20139."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:45:10Z","timestamp":1765331110000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/dta.3953"],"URL":"https:\/\/doi.org\/10.1002\/dta.3953","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"2025-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}